# Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

> **NCT02374099** · PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 97 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** CC-486
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02374099
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-13
- **Primary completion:** 2016-12-13
- **Final completion:** 2017-11-21
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2018-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02374099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02374099, "Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02374099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*